DOES OVARIAN STIMULATION FOR INVITRO FERTILIZATION INDUCE A HYPERCOAGULABLE STATE

被引：71

作者：

AUNE, B

HOIE, KE

OIAN, P

HOLST, N

OSTERUD, B

机构：

[1] Department of Obstetrics and Gynaecology, Institute of Medical Biology, University of Tromsø, Tromsø

来源：

HUMAN REPRODUCTION | 1991年 / 6卷 / 07期

关键词：

COAGULATION; FIBRINOLYSIS; IVF;

D O I：

10.1093/oxfordjournals.humrep.a137461

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Effects on blood coagulation and fibrinolytic activity during ovarian stimulation for in-vitro fertilization (IVF) were examined in 12 women. Blood samples were taken prior to hormonal stimulation (days 2-3 of the menstrual cycle, mean serum oestradiol concentration 0.16 nmol/l) and the day after ovulation induction with human chorionic gonadotrophin (HCG) (days 10-12, mean serum oestradiol concentration 5.35 nmol/l). We measured whole blood clotting time, whole blood clot lysis time, plasma fibrinogen, factor VII and antithrombin III. The whole blood clotting time was slightly, but not significantly shortened after ovarian stimulation. A significant rise in plasma fibrinogen (P < 0.001) and reduction in antithrombin III (P < 0.001) were observed, whereas no change in factor VII was found. The blood fibrinolytic activity was significantly reduced as evaluated by an increase in the clot lysis time (P < 0.02). These results indicate that ovarian stimulation for IVF may create a state of hypercoagulability.

引用

页码：925 / 927

页数：3

共 17 条

[1]

Astedt B., Jeppsson S., 17-/3-oestradioI and the fibrinolytic activity of vein walls, J.Obstet.Gynaecol.Br.Commonw, 81, pp. 719-723, (1974)

[2]

Beller F.K., Ebert C., The coagulation and fibrinolytic enzyme system in pregnancy and in the puerperium, Eur.J.Obstet.Gynecol Reprod.Biol, 13, pp. 177-197, (1982)

[3]

Bonnard, Coagulation effects of oral contraception, Am.J.Obstet Gynecol, 15, pp. 1042-1048, (1987)

[4]

Bush T.L., Barrett-Connor E., Noncontraceptive estrogen use and cardiovascular disease.Epidemiol, Rev, 7, pp. 80-104, (1985)

[5]

Chohan L.S., Vermeulen J., Singh I., Balakrishnan K., Verstraete M., Sodium acetate buffer.A diluent of choice in the clot lysis time technique.Thromb.Diathes, Haemorrh, 33, pp. 226-229, (1975)

[6]

Conard J., Samama M., Salomon Y., Antithrombin III and the oestrogen content of combined oestro-progestagen contraceptives, Lancet, Ii, pp. 1148-1149, (1972)

[7]

Holst N., Bertheussen K., Forsdahl F.H., Konsen M.B., Jul Hansen L., Nielsen H.I., Optimization and simplification of culture conditions in human in vitro fertilization and pre-embryo replacement by serum-free media.J, Vitro Fertil Embryo Transfer, 7, pp. 47-53, (1990)

[8]

Inada Y., Okamoto H., Kanai S., Tamaura Y., Faster determination of clottable fibrinogen in human plasma: An improved method and kinetic study, Clin.Chem, 24, pp. 351-353, (1978)

[9]

Kim H.C., Kemmann E., Shelden R.M., Saidi P., Response of blood coagulation parameters to elevated endogenous 17 /3-estradiol levels induced by human menopausal gonadotrophins, Am.J.Obstet.Gynecol, 14, pp. 807-810, (1981)

[10]

Mann J., Inman W.H.W., Oral contraceptives and death from myocardial infarction, Br.Med.J, 2, pp. 245-248, (1975)

← 1 2 →